Source:http://linkedlifedata.com/resource/pubmed/id/11787527
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0009647,
umls-concept:C0010583,
umls-concept:C0040113,
umls-concept:C0181586,
umls-concept:C0205263,
umls-concept:C0205360,
umls-concept:C0205430,
umls-concept:C0229601,
umls-concept:C0333678,
umls-concept:C0443252,
umls-concept:C1515655,
umls-concept:C1522449,
umls-concept:C1533691,
umls-concept:C1704410
|
| pubmed:issue |
12
|
| pubmed:dateCreated |
2002-1-11
|
| pubmed:abstractText |
Successful transplantation of solid organs relies on long-term immunosuppression for the prevention of graft rejection. Donor-specific tolerance without the need for continuous immunosuppression can be observed after allogeneic BMT. However, its routine use for tolerance induction has been precluded so far by the high conditioning-related toxicity of standard BMT regimens. Our laboratory has recently established a cyclophosphamide (CTX) plus thymic irradiation (TI)-based nonmyeloablative conditioning protocol for the treatment of hematologic malignancies. We have recently described the successful clinical application of this approach for the induction of donor-specific tolerance in a patient receiving a living-related kidney transplant, which resulted in graft acceptance without long-term immunosuppression. The aim of this study was to evaluate the induction and maintenance of host-versus-graft tolerance following this CTX-plus-TI-based regimen in a mouse model.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1083-8791
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
7
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
646-55
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:11787527-Animals,
pubmed-meshheading:11787527-Antibodies, Monoclonal,
pubmed-meshheading:11787527-Bone Marrow Transplantation,
pubmed-meshheading:11787527-Cyclophosphamide,
pubmed-meshheading:11787527-Female,
pubmed-meshheading:11787527-Graft Survival,
pubmed-meshheading:11787527-Hematopoiesis,
pubmed-meshheading:11787527-Histocompatibility,
pubmed-meshheading:11787527-Immune Tolerance,
pubmed-meshheading:11787527-Immunosuppressive Agents,
pubmed-meshheading:11787527-Lymphocyte Depletion,
pubmed-meshheading:11787527-Male,
pubmed-meshheading:11787527-Mice,
pubmed-meshheading:11787527-Mice, Inbred Strains,
pubmed-meshheading:11787527-Models, Animal,
pubmed-meshheading:11787527-Skin Transplantation,
pubmed-meshheading:11787527-T-Lymphocytes,
pubmed-meshheading:11787527-Thymus Gland,
pubmed-meshheading:11787527-Transplantation, Homologous,
pubmed-meshheading:11787527-Transplantation Chimera,
pubmed-meshheading:11787527-Transplantation Conditioning
|
| pubmed:year |
2001
|
| pubmed:articleTitle |
Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
|
| pubmed:affiliation |
Transplantation Biology Research Center, Bone Marrow Transplantation Section, Massachusetts General Hospital, Harvard Medical School, Boston 02129, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|